[go: up one dir, main page]

CO6680624A2 - Tratamiento de queloide - Google Patents

Tratamiento de queloide

Info

Publication number
CO6680624A2
CO6680624A2 CO13015329A CO13015329A CO6680624A2 CO 6680624 A2 CO6680624 A2 CO 6680624A2 CO 13015329 A CO13015329 A CO 13015329A CO 13015329 A CO13015329 A CO 13015329A CO 6680624 A2 CO6680624 A2 CO 6680624A2
Authority
CO
Colombia
Prior art keywords
treating
keloid
scar keloid
scar
treatment
Prior art date
Application number
CO13015329A
Other languages
English (en)
Inventor
Adebola O E Obayan
Sanjeev Singh
Brenda Collen Joyce Yuzdepski
Original Assignee
Adetherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adetherapeutics filed Critical Adetherapeutics
Publication of CO6680624A2 publication Critical patent/CO6680624A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona un método de tratar o prevenir o tratar profilácticamente un queloide cicatricial. En una modalidad preferida se provee un método de tratar o prevenir o tratar profilácticamente un queloide cicatricial, método que comprende administrar tópicamente a un sitio de formación de queloide cicatricial o formación potencial de queloide cicatricial una cantidad efectiva de L-alanil-L-glutamina en un organogel. La invención es útil en el tratamiento de queloide cicatricial.
CO13015329A 2010-06-28 2013-01-28 Tratamiento de queloide CO6680624A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35905310P 2010-06-28 2010-06-28

Publications (1)

Publication Number Publication Date
CO6680624A2 true CO6680624A2 (es) 2013-05-31

Family

ID=45401271

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13015329A CO6680624A2 (es) 2010-06-28 2013-01-28 Tratamiento de queloide

Country Status (13)

Country Link
US (1) US20140005116A1 (es)
EP (1) EP2585090A4 (es)
JP (1) JP2013533867A (es)
KR (1) KR20130089174A (es)
CN (1) CN103002903B (es)
AU (1) AU2011274224A1 (es)
BR (1) BR112012033349A2 (es)
CA (1) CA2804413A1 (es)
CO (1) CO6680624A2 (es)
MX (1) MX2013000107A (es)
RU (1) RU2578426C2 (es)
WO (1) WO2012000113A1 (es)
ZA (1) ZA201209759B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11000545B2 (en) 2013-03-15 2021-05-11 Cda Research Group, Inc. Copper ion compositions and methods of treatment for conditions caused by coronavirus and influenza
US11318089B2 (en) 2013-03-15 2022-05-03 Cda Research Group, Inc. Topical copper ion treatments and methods of making topical copper ion treatments for use in various anatomical areas of the body
US10398733B2 (en) 2013-03-15 2019-09-03 Cda Research Group, Inc. Topical copper ion treatments and methods of treatment using topical copper ion treatments in the dermatological areas of the body
US12318406B2 (en) 2013-03-15 2025-06-03 Cda Research Group, Inc. Methods of treatment using topical copper ion formulations
FR3004353B1 (fr) * 2013-04-10 2015-05-15 Fabre Pierre Dermo Cosmetique Association synergique de l'alanine-glutamine, l'acide hyaluronique et un extrait d'avoine, et son utilisation dans une composition destinee a la cicatrisation et la reparation des lesions cutanees
KR101800788B1 (ko) * 2017-03-31 2017-11-27 박영오 켈로이드 흉터 개선용 화장료 조성물
US10500318B1 (en) * 2018-07-03 2019-12-10 Temple Therapeutics BV Dosing regimens for treating hypoxia-associated tissue damage
US11193184B2 (en) 2019-02-22 2021-12-07 Cda Research Group, Inc. System for use in producing a metal ion suspension and process of using same
CN114767590B (zh) * 2022-04-20 2024-03-15 上海交通大学医学院附属第九人民医院 一种祛疤祛痘印美容液及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5740409A (en) * 1980-08-22 1982-03-06 Mitsui Toatsu Chem Inc Remedy for disease caused by extraordinary propagation of collagen
US6149925A (en) * 1998-11-05 2000-11-21 Color Access, Inc. Topical compositions for enhancing glutathione production
WO2001014527A1 (en) * 1999-08-23 2001-03-01 Organogenesis Inc. Skin care compositions and treatments
JP2004532230A (ja) * 2001-04-30 2004-10-21 アラクノーバ・セラピューティックス・リミテッド Ｐｐａｒ−ガンマアクチベーターを使用する瘢痕化および関連状態の処置
US20030105025A1 (en) * 2001-10-31 2003-06-05 Fortuna Haviv Tri-and tetrapeptides having antiangiogenic activity
RU2234963C2 (ru) * 2002-09-16 2004-08-27 Сибирский государственный медицинский университет Способ лечения гипертрофических и келоидных кожных рубцов
ES2389805T3 (es) * 2003-09-12 2012-10-31 University Of Colorado Glutamina para su uso en el tratamiento de una lesión
RU2275216C1 (ru) * 2004-12-08 2006-04-27 Елена Григорьевна Арий Способ профилактики формирования патологических кожных рубцов
PL1940439T3 (pl) * 2005-08-11 2011-04-29 Univ Saskatchewan Zmniejszanie tworzenia pooperacyjnych zrostów przez dootrzewnowe podawanie glutaminy
WO2007056068A2 (en) * 2005-11-02 2007-05-18 Bentley Pharmaceuticals, Inc. Macrocyclic formulations for transmembrane drug delivery
CN100372522C (zh) * 2005-12-02 2008-03-05 何秋莎 护肤品
CA2578647A1 (en) * 2007-02-15 2008-08-15 University Of Saskatchewan Reducing post-operative adhesion formation with intraperitoneal glutamine

Also Published As

Publication number Publication date
CN103002903A (zh) 2013-03-27
MX2013000107A (es) 2013-06-03
BR112012033349A2 (pt) 2016-10-11
EP2585090A1 (en) 2013-05-01
RU2013103507A (ru) 2014-08-10
AU2011274224A8 (en) 2014-09-18
RU2578426C2 (ru) 2016-03-27
AU2011274224A1 (en) 2013-01-17
EP2585090A4 (en) 2014-01-15
CA2804413A1 (en) 2012-01-05
ZA201209759B (en) 2014-03-26
US20140005116A1 (en) 2014-01-02
WO2012000113A1 (en) 2012-01-05
KR20130089174A (ko) 2013-08-09
CN103002903B (zh) 2015-04-22
JP2013533867A (ja) 2013-08-29
HK1183626A1 (en) 2014-02-14

Similar Documents

Publication Publication Date Title
CO6680624A2 (es) Tratamiento de queloide
UA110338C2 (xx) Хімічні сполуки
CO6761389A2 (es) Inhibidores de nampt y rock
UA110813C2 (uk) Лікування ліподистрофії
ECSP13012420A (es) Derivados de tetrahidro-pirido-pirimidina
MX2013003076A (es) Terapeuticos contra cancer de mama.
CR20130464A (es) Inhibidores sustituidos de acetil-coa carboxilasa
UA111148C2 (uk) Сигма-ліганди для застосування при профілактиці і/або лікуванні післяопераційного болю
MX2014005440A (es) Inhibidores de nicotinamida adenina dinucleotido difosfato oxidasa-4 y uso de los mismos.
ECSP14030779A (es) Inhibidores del nampt
CR20120551A (es) Mètodo para el tratamiento de un lìquido, en particular un aceite mineral
BR112013020159A2 (pt) método para inibir células tumorais de hamartoma
ITMI20120370A1 (it) Miscela antimicrobica e rivestimento per supportare la guarigione di ferite, che ha un effetto antimicrobico.
MX378581B (es) Composiciones y metodos para la mineralizacion dental.
EP2576536A4 (en) HEMATOPOETIC PROSTAGLANDIN D2 SYNTHASE INHIBITORS
MX2013013281A (es) Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca.
UA115052C2 (uk) Конденсоване біциклічне 2,4-діамінопіримідинове похідне як подвійний alk- i fak-інгібітор
EA201201296A1 (ru) Способы лечения диабетических язв стопы
AR089320A1 (es) Cepa de lactobacillus mucosae
GT201400038A (es) Composiciones y métodos para tratar el cáncer usando el inhibidor de p13kbeta y el inhibidor de la vía de mapk, incluidos los inhibidores de mek y raf
MX348397B (es) Uso de extractos de filipendula para el tratamiento y profilaxis de dolor crónico.
MX2013010050A (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
MX2015011567A (es) Halogeno-pirazoles como inhibidores de trombina.
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
EA201491581A1 (ru) Везикулярные композиции